Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

The Lancet Oncology
Andrew J ArmstrongDaniel J George

Abstract

Non-clear cell renal cell carcinomas are histologically and genetically diverse kidney cancers with variable prognoses, and their optimum initial treatment is unknown. We aimed to compare the mTOR inhibitor everolimus and the VEGF receptor inhibitor sunitinib in patients with non-clear cell renal cell carcinoma. We enrolled patients with metastatic papillary, chromophobe, or unclassified non-clear cell renal cell carcinoma with no history of previous systemic treatment. Patients were randomly assigned (1:1) to receive everolimus (10 mg/day) or sunitinib (50 mg/day; 6-week cycles of 4 weeks with treatment followed by 2 weeks without treatment) administered orally until disease progression or unacceptable toxicity. Randomisation was stratified by Memorial Sloan Kettering Cancer Center risk group and papillary histology. The primary endpoint was progression-free survival in the intention-to-treat population using the RECIST 1.1 criteria. Safety was assessed in all patients who were randomly assigned to treatment. This study is registered with ClinicalTrials.gov, number NCT01108445. Between Sept 23, 2010, and Oct 28, 2013, 108 patients were randomly assigned to receive either sunitinib (n=51) or everolimus (n=57). As of December, 2...Continue Reading

References

Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerMadhu Mazumdar
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael B AtkinsMatthew L Sherman
Jan 27, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·W Marston LinehanLen Neckers
May 12, 2007·European Urology·Paul C M S Verhagen
Jun 1, 2007·The New England Journal of Medicine·Gary HudesUNKNOWN Global ARCC Trial
Jan 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Toni K ChoueiriBernard Escudier
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bernard EscudierRonald M Bukowski
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniEric J Small
Aug 25, 2011·Current Clinical Pharmacology·Rhonda L BittingAndrew J Armstrong
Jan 10, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J-L LeeH Ahn
Aug 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew J ArmstrongSusan Halabi
Nov 28, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y KohS-H Lee
Dec 6, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Toni K ChoueiriRamaprasad Srinivasan
Jul 23, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerJennifer J Knox
Aug 27, 2014·Cancer Cell·Caleb F DavisChad J Creighton
Sep 7, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T K ChoueiriS Signoretti

❮ Previous
Next ❯

Citations

Mar 15, 2016·The Lancet Oncology·Sebastiano Buti, Melissa Bersanelli
Jun 30, 2016·Acta Clinica Belgica·T VermassenSylvie Rottey
Jun 25, 2016·International Journal of Molecular Sciences·Moto Kajiwara, Satohiro Masuda
Jul 28, 2016·Cancer Treatment Reviews·Chiara CiccareseFrancesco Massari
Aug 5, 2016·British Journal of Cancer·Basma Greef, Tim Eisen
Sep 30, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Bernard EscudierLaurence Albiges
Dec 15, 2016·Expert Review of Anticancer Therapy·Elise NassifStéphane Oudard
Sep 25, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B EscudierUNKNOWN ESMO Guidelines Committee
Sep 8, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin H VossDarren R Feldman
Sep 8, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sumanta K PalNeeraj Agarwal
Mar 10, 2017·Nature Reviews. Disease Primers·James J HsiehVincenzo Ficarra
Mar 18, 2017·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Zhang YueXue Feng-Xia
Jan 22, 2017·Clinical Genitourinary Cancer·Sebastiano ButiOrazio Caffo
Jan 11, 2017·Nature Reviews. Clinical Oncology·Laurence Albiges, Toni K Choueiri
Mar 3, 2017·Current Opinion in Oncology·Mark W BallRamaprasad Srinivasan
Jan 26, 2017·The New England Journal of Medicine·Toni K Choueiri, Robert J Motzer
Dec 3, 2016·Therapeutic Advances in Urology·Thomas A Schmid, Martin E Gore
Jul 25, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian ShuchNeeraj Agarwal
Mar 21, 2018·Expert Opinion on Drug Metabolism & Toxicology·Delia De LisiAlberto Farolfi
May 27, 2017·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Ki Sun JungHo Yeong Lim
Sep 30, 2017·CA: a Cancer Journal for Clinicians·Pedro C Barata, Brian I Rini
Sep 28, 2017·Expert Opinion on Investigational Drugs·Michele GhidiniSandro Barni
Sep 29, 2017·Expert Review of Clinical Pharmacology·Alessia MennittoGiuseppe Procopio
Feb 22, 2018·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·J J KoldenhofP O Witteveen
Sep 22, 2017·PloS One·Nina WagenerUNKNOWN European Association of Urology (EAU) Young Academic Urologists (YAU) Kidney Cancer Group
Jan 26, 2018·Current Treatment Options in Oncology·Ulka Vaishampayan
Jan 31, 2018·Journal for Immunotherapy of Cancer·Vadim S KoshkinBrian I Rini
Dec 7, 2018·Advances in Anatomic Pathology·Mohammed AkhtarTurki Al Hussain
Feb 26, 2019·Oncology Research and Treatment·Marit AhrensUNKNOWN IAG-N Interdisciplinary Working Group Kidney Cancer of the German Cancer Society
Feb 23, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B EscudierUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Nov 14, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bradley A McGregorToni K Choueiri
Jun 1, 2017·American Society of Clinical Oncology Educational Book·Tian ZhangSumanta K Pal
Sep 27, 2019·Expert Opinion on Investigational Drugs·Lakshminarayanan NandagopalNeeraj Agarwal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Adenocarcinoma, Clear Cell

Clear Cell Adenocarcinoma is a tumor that arises in the female genital tract and is characterized by cells that appear clear under the microscope. Discover the latest research here.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.